Table 3.
Demographic and clinical data of 93 patients who fulfilled the 1993 pSS criteria: comparison between 59 patients who fulfilled both the 1993 and 2002/2012 pSS criteria, and 34 patients who only fulfilled the pSS 1993 criteria.
|
Total |
pSS fulfilling 2002/2012 criteria |
pSS fulfilling only 1993 criteria |
p |
|
|---|---|---|---|---|
| n = 93 | n = 59 | n = 34 | ||
| Age at disease onset, years (n = 88) | 49.5 ± 13.2 | 48.1 ± 12.6 | 52.0 ± 14.0 | 0.179 |
| Female | 86 (92.5) | 56 (88.2) | 30 (94.9) | 0.240 |
| Disease duration, years (n = 88) | 12.3 ± 6.6 | 13.7 ± 6.7 | 9.9 ± 5.7 | 0.008 |
| ESSDAI | 0.90 ± 1.46 | 1.27 ± 1.64 | 0.94 ± 1.37 | 0.301 |
| Elevated ESR | 47 (50.5) | 30 (50.8) | 17 (50.0) | 0.937 |
| Pathologic SGU (grade 2 or 3) | 32 (34.5) | 31 (52.5) | 1 (2.9) | <0.001 |
| Lymphoma | 3 (3.2) | 2 (3.4) | 1 (2.9) | 0.173 |
| Autoimmune thyroiditis | 27 (29.0) | 20 (33.9) | 7 (20.6) | 0.138 |
| Extraglandular involvement | 76 (81.7) | 46 (78.0) | 30 (88.2) | 0.217 |
| Parotid swelling | 12 (12.9) | 4 (6.8) | 8 (23.5) | 0.020 |
Data are presented as mean ± standard deviation or n (%).
pSS: primary Sjögren’s syndrome; SGU: salivary gland ultrasound; ESSDAI: European League Against Rheumatism Sjögren’s syndrome disease activity index; ESR: erythrocyte sedimentation rate.